Additional Relevant Details Theravance Biopharma today announced that data from new studies of VIBATIV (telavancin) will be presented at the American Society of Microbiology (ASM) Microbe 2016 Conference, being held in Boston, MA, on June 16-20, 2016. New data on the potent in vitro activity of VIBATIV against isolates from a range of difficult-to-treat infections, including methicillin-resistant Staphylococcus aureus (MRSA), will be highlighted in several poster presentations at the conference.